Clinical Trial Update: An Open-Label, Pilot Study to Evaluate the Development of Resistance to Nevirapine (BI-RG-587) in HIV-Infected Patients With CD4 Cell Count >= 500/mm3 [Phase 2]

View source ↗

Summary

An open-label Phase 2 pilot study evaluating the development of resistance to the antiretroviral Nevirapine (BI-RG-587) in HIV-infected patients with CD4 counts…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• BI-RG-587
• NEVIRAPINE (nevirapine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 2 | Status: COMPLETED